Latest Commercial Scale Up News

Energy Fuels Inc. reported a transformative 2024 with a major acquisition boosting its heavy mineral sands assets, a uranium production ramp-up at key US mines, and commercial rare earth oxide output from its White Mesa Mill.

BCI Minerals has contracted Bluestar Lehigh to build a 150 kg/hr sulphate of potash pilot plant at Mardie, aiming to de-risk commercial SOP production. Commissioning is set for early FY2028 with piloting to span about a year, funded within the existing $1.443 billion Mardie budget.

Locksley Resources has ceased active exploration at its US critical minerals projects following a technical review and a sharp drop in antimony prices, opting to maintain claims on a low-cost basis while reassessing its hydrometallurgical technology partnership.

Hazer Group and KBR have secured a paid pre-feasibility study with a leading Japanese power utility to explore large-scale deployment of methane pyrolysis technology, reinforcing Hazer's foothold in Japan's clean hydrogen market.

Podium Minerals has secured a $4 million underwritten share purchase plan to fund advancing metallurgical work and site rehabilitation at its Parks Reef PGM Project, following a significant step-change in concentrator performance.

Metal Powder Works accelerates its capacity expansion to meet surging demand in additive manufacturing and powder metallurgy, leveraging its NextGen DirectPowder™ platform and a key production order.

Lindian Resources has acquired 100% ownership of the SARECO rare earths processing plant in Kazakhstan, accelerating its downstream ambitions, while also clarifying regulatory compliance and licence validity at its Kangankunde project in Malawi.

Austral Resources has locked in $15 million from QIC’s Queensland Critical Minerals Fund to advance expansion planning at its Rocklands copper processing facility, aiming to boost capacity beyond 3Mtpa and extend operational life through 2034 and beyond.

Iondrive has launched its first five-tonne IONSolv™ production campaign in North America, aiming to produce about 1.4 tonnes of mixed rare earth oxide from recycled permanent magnets by Q4 2026. This milestone bridges lab validation and commercial-scale plans while supporting US supply chain independence.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Eden Innovations reported strong EdenCrete® trial results in India and North America, strategic hires for EdenShield® in defence markets, and completed a $4.05 million placement, ending the quarter debt-free with $5.2 million cash.

Iondrive Limited has independently confirmed strong rare earth recoveries from U.S. magnet waste and gained Oklahoma government support for its first commercial processing module, advancing its U.S. commercialisation strategy.